OP-047 Initial Experience on the Use of Novel Oral Anticoagulants (NOAC) in Adults with Congenital Heart Disease

Electrophysiology Updates in Adult Congenital Heart Disease

“…13 One quarter of the patients in Aristotle (Apixaban versus Warfarin in Patients with Atrial Fibrillation Trial) 14 had moderate or severe valve disease (most often mitral regurgitation). A German series 15 that was presented at the 11th International Congress of Update in Cardiology and Cardiovascular Surgery (2015) had 55 ACHD patients on NOACs, half of whom had greatly complex cases (3 with anatomy that suggested Fontan circulation). In only 1 patient was the NOAC discontinued for bleeding associated with muscular rupture.…”

“…In only 1 patient was the NOAC discontinued for bleeding associated with muscular rupture. 15 Ongoing studies should focus on demonstrating the safety and efficacy of these novel medications in this problematic population so that they too might reap the benefit of medical advances.…”